Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK1 | P23458 | 3/20 | 0.59 |
| ▸ | JAK3 | P52333 | 3/20 | 0.59 |
| ▸ | JAK2 | O60674 | 1/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.59 |
| ▸ | EGFR | P00533 | 1/20 | 0.56 |
| ▸ | BRD4 | O60885 | 14/20 | 0.51 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.51 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL340421 | 1.00 | JAK1 (0.59) | JAK1JAK3JAK2CYP3A4EGFR | |
| SCHEMBL341397 | 0.88 | JAK1 (0.75) | JAK1JAK3JAK2CYP3A4EGFR | |
| SCHEMBL29610195 | 0.88 | JAK1 (0.75) | JAK1JAK3JAK2CYP3A4EGFR | |
| SCHEMBL340099 | 0.86 | JAK1 (0.80) | JAK1JAK3JAK2CYP3A4 | |
| SCHEMBL29609909 | 0.86 | JAK1 (0.80) | JAK1JAK3JAK2CYP3A4 | |
| SCHEMBL29610790 | 0.79 | JAK1 (0.78) | JAK1JAK3JAK2CYP3A4 | |
| SCHEMBL341081 | 0.79 | JAK1 (0.78) | JAK1JAK3JAK2CYP3A4 | |
| SCHEMBL340163 | 0.79 | JAK1 (0.77) | JAK1JAK3JAK2CYP3A4 | |
| SCHEMBL3102212 | 0.79 | JAK1 (0.60) | JAK1JAK3JAK2CYP3A4EGFR | |
| SCHEMBL13268190 | 0.79 | JAK1 (0.54) | JAK1JAK3JAK2CYP3A4EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4009974-A1 | COMPOUNDS AND METHOD FOR TREATING CYTOKINE RELEASE SYNDROME | Rigel Pharmaceuticals, Inc. (US) | 2022-06-15 | — | — | EP | disclosed |